Viewing Study NCT05136235


Ignite Creation Date: 2025-12-24 @ 10:23 PM
Ignite Modification Date: 2025-12-24 @ 10:23 PM
Study NCT ID: NCT05136235
Status: NOT_YET_RECRUITING
Last Update Posted: 2021-11-29
First Post: 2021-10-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Pulmonary Hypertension in Extremely Preterm Infants
Sponsor: Universitair Ziekenhuis Brussel
Organization:

Study Overview

Official Title: Pulmonary Hypertension in Extremely Preterm Infants - A Prospective Cohort Study
Status: NOT_YET_RECRUITING
Status Verified Date: 2021-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PiEP
Brief Summary: Extremely preterm infants are at risk for developing bronchopulmonary dysplasia (BPD) and associated chronic pulmonary hypertension (PH), a consequence of altered pulmonary vasculature. This condition occurs in about 25% of babies with BPD, and the association grows with increasing BPD severity. Other risk factors have been described as well. Morbidity and mortality associated with prematurity and/or BPD increase significantly in the presence of PH.

Thus, international guidelines encourage the use of standardized screening protocols for this condition. However, several questions regarding these recommendations are left unanswered, such as a clear definition for PH in this population.

The research aim is to prospectively evaluate prevalence, risk factors and clinical course of PH in these children. The investigators aim to identify at-risk infants early on and ultimately improve survival making use of an early targeted intervention.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: